1
|
Lorente L, Martín MM, Ortiz-López R, González-Rivero AF, Gómez-Bernal F, González-Mesa A, Jiménez A, Pérez-Cejas A. High mortality rate of septic patients with high blood granzyme B concentrations. Diagn Microbiol Infect Dis 2022; 103:115694. [DOI: 10.1016/j.diagmicrobio.2022.115694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Revised: 03/05/2022] [Accepted: 03/16/2022] [Indexed: 11/03/2022]
|
2
|
Covarrubias-Zambrano O, Motamedi M, Ameredes BT, Tian B, Calhoun WJ, Zhao Y, Brasier AR, Kalubowilage M, Malalasekera AP, Yapa AS, Wang H, Culbertson CT, Troyer DL, Bossmann SH. Optical biosensing of markers of mucosal inflammation. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2021; 40:102476. [PMID: 34743019 DOI: 10.1016/j.nano.2021.102476] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 09/13/2021] [Accepted: 10/01/2021] [Indexed: 02/07/2023]
Abstract
We report the design and adaptation of iron/iron oxide nanoparticle-based optical nanobiosensors for enzymes or cytokine/chemokines that are established biomarkers of lung diseases. These biomarkers comprise ADAM33, granzyme B, MMP-8, neutrophil elastase, arginase, chemokine (C-C motif) ligand 20 and interleukin-6. The synthesis of nanobiosensors for these seven biomarkers, their calibration with commercially available enzymes and cytokines/chemokines, as well as their validation using bronchoalveolar lavage (BAL) obtained from a mouse model of TLR3-mediated inflammation are discussed here. Exhaled Breath Condensate (EBC) is a minimally invasive approach for sampling airway fluid in the diagnosis and management of various lung diseases in humans (e.g., asthma, COPD and viral infections). We report the proof-of-concept of using human EBC in conjunction with nanobiosensors for diagnosis/monitoring airway inflammation. These findings suggest that, with nanosensor technology, human EBC can be utilized as a liquid biopsy to monitor inflammation/remodeling in lung disease.
Collapse
Affiliation(s)
| | - Massoud Motamedi
- Center for Biomedical Engineering, University of Texas Medical Branch, Galveston, TX, USA
| | - Bill T Ameredes
- Institute for Translational Sciences and Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX
| | - Bing Tian
- Institute for Translational Sciences and Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX
| | - William J Calhoun
- Institute for Translational Sciences and Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX
| | - Yingxin Zhao
- Institute for Translational Sciences and Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX
| | - Allan R Brasier
- Institute for Clinical and Translational Research, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI
| | | | - Aruni P Malalasekera
- Department of Chemistry, Southwestern College, 100 College Street, Winfield, KS, USA
| | - Asanka S Yapa
- Department of Chemistry, Kansas State University, Manhattan, KS, USA
| | - Hongwang Wang
- Department of Chemistry, Kansas State University, Manhattan, KS, USA
| | | | - Deryl L Troyer
- Department of Anatomy & Physiology, Kansas State University, Manhattan, KS, USA
| | - Stefan H Bossmann
- Department of Chemistry, Kansas State University, Manhattan, KS, USA; The University of Kansas Medical Center, Department of Cancer Biology and The University of Kansas Cancer Center, Kansas City, KS, USA.
| |
Collapse
|
3
|
Rasi V, Wood DC, Eickhoff CS, Xia M, Pozzi N, Edwards RL, Walch M, Bovenschen N, Hoft DF. Granzyme A Produced by γ 9δ 2 T Cells Activates ER Stress Responses and ATP Production, and Protects Against Intracellular Mycobacterial Replication Independent of Enzymatic Activity. Front Immunol 2021; 12:712678. [PMID: 34413857 PMCID: PMC8368726 DOI: 10.3389/fimmu.2021.712678] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Accepted: 07/12/2021] [Indexed: 01/14/2023] Open
Abstract
Mycobacterium tuberculosis (Mtb), the pathological agent that causes tuberculosis (TB) is the number one infectious killer worldwide with one fourth of the world's population currently infected. Data indicate that γ9δ2 T cells secrete Granzyme A (GzmA) in the extracellular space triggering the infected monocyte to inhibit growth of intracellular mycobacteria. Accordingly, deletion of GZMA from γ9δ2 T cells reverses their inhibitory capacity. Through mechanistic studies, GzmA's action was investigated in monocytes from human PBMCs. The use of recombinant human GzmA expressed in a mammalian system induced inhibition of intracellular mycobacteria to the same degree as previous human native protein findings. Our data indicate that: 1) GzmA is internalized within mycobacteria-infected cells, suggesting that GzmA uptake could prevent infection and 2) that the active site is not required to inhibit intracellular replication. Global proteomic analysis demonstrated that the ER stress response and ATP producing proteins were upregulated after GzmA treatment, and these proteins abundancies were confirmed by examining their expression in an independent set of patient samples. Our data suggest that immunotherapeutic host interventions of these pathways may contribute to better control of the current TB epidemic.
Collapse
Affiliation(s)
- Valerio Rasi
- Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States,Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, United States
| | - David C. Wood
- Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, MO, United States
| | - Christopher S. Eickhoff
- Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, United States
| | - Mei Xia
- Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, United States
| | - Nicola Pozzi
- Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, MO, United States
| | - Rachel L. Edwards
- Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, United States
| | - Michael Walch
- Anatomy Unit, Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
| | - Niels Bovenschen
- Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands,Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
| | - Daniel F. Hoft
- Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States,Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, United States,*Correspondence: Daniel F. Hoft,
| |
Collapse
|
4
|
Zhang Q, Wang J, Huang F, Yao Y, Xu L. Leptin induces NAFLD progression through infiltrated CD8+ T lymphocytes mediating pyroptotic-like cell death of hepatocytes and macrophages. Dig Liver Dis 2021; 53:598-605. [PMID: 33172809 DOI: 10.1016/j.dld.2020.10.025] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2020] [Revised: 09/29/2020] [Accepted: 10/15/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease, which causes serious health problems worldwide. Hyperleptinemia and inflammatory stress are crucial in the progression of NAFLD. However, the relationship between leptin and immune cells or hepatocytes is still unclear. AIMS This study aimed to clarify the regulatory mechanism of leptin-mediated disease progression through immune cells and its relationship with hepatocytes. METHODS An NAFLD rat model was established to verify the relationship between hyperleptinemia and CD8+ T lymphocytes and cytokines in liver tissue. CD8+ T lymphocytes isolated from blood mononuclear cells were co-cultured with macrophages or hepatocytes stimulated with leptin or treated with granzyme inhibitors to observe target cell morphology and expression of pivotal protein family members. RESULTS CD8+ T lymphocyte infiltration positively correlated with blood leptin, IL-18 and IL-1β levels and was related to macrophage recruitment and differentiation in a rat model of NAFLD. Leptin could induce activated caspase-1 and caspase-3 in hepatocytes and trigger hepatocyte pyroptosis. CONCLUSIONS Leptin may regulate the pyroptotic-like death of macrophages and hepatocytes through CD8+ T lymphocytes in NAFLD progression. The intervention of related pathways of leptin and immune cells may provide a promising strategy for treating NAFLD.
Collapse
Affiliation(s)
- Qinghui Zhang
- Department of Clinical Laboratory, Kunshan First People's Hospital, Jiangsu University, Kunshan 215300, China.
| | - Jianjun Wang
- Department of Clinical Laboratory, Kunshan First People's Hospital, Jiangsu University, Kunshan 215300, China
| | - Feng Huang
- Department of Clinical Laboratory, Kunshan First People's Hospital, Jiangsu University, Kunshan 215300, China
| | - Yongliang Yao
- Department of Clinical Laboratory, Kunshan First People's Hospital, Jiangsu University, Kunshan 215300, China
| | - Ling Xu
- Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, China.
| |
Collapse
|
5
|
Ahmad J, Ikram S, Hafeez AB, Durdagi S. Physics-driven identification of clinically approved and investigation drugs against human neutrophil serine protease 4 (NSP4): A virtual drug repurposing study. J Mol Graph Model 2020; 101:107744. [PMID: 33032202 DOI: 10.1016/j.jmgm.2020.107744] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 08/29/2020] [Accepted: 08/31/2020] [Indexed: 01/19/2023]
Abstract
Neutrophils synthesize four immune associated serine proteases: Cathepsin G (CTSG), Elastase (ELANE), Proteinase 3 (PRTN3) and Neutrophil Serine Protease 4 (NSP4). While previously considered to be immune modulators, overexpression of neutrophil serine proteases correlates with various disease conditions. Therefore, identifying novel small molecules that can potentially control or inhibit the proteolytic activity of these proteases is crucial to revert or temper the aggravated disease phenotype. To the best of our knowledge, although there is limited data for inhibitors of other neutrophil protease members, there is no previous clinical study of a synthetic small molecule inhibitor targeting NSP4. In this study, an integrated molecular modeling algorithm was performed within a virtual drug repurposing study to identify novel inhibitors for NSP4, using clinically approved and investigation drugs library (∼8000 compounds). Based on our rigorous filtration, we found that following molecules Becatecarin, Iogulamide, Delprostenate and Iralukast are predicted to block the activity of NSP4 by interacting with core catalytic residues. The selected ligands were energetically more favorable compared to the reference molecule. The result of this study identifies promising molecules as potential lead candidates.
Collapse
Affiliation(s)
- Jamshaid Ahmad
- Center of Biotechnology & Microbiology, University of Peshawar, Pakistan.
| | - Saima Ikram
- Center of Biotechnology & Microbiology, University of Peshawar, Pakistan; Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahcesehir University, Istanbul, Turkey
| | - Ahmer Bin Hafeez
- Center of Biotechnology & Microbiology, University of Peshawar, Pakistan
| | - Serdar Durdagi
- Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahcesehir University, Istanbul, Turkey.
| |
Collapse
|
6
|
Dencker M, Björgell O, Hlebowicz J. Effect of food intake on 92 oncological biomarkers by the Proseek Oncology II panel. BMC Res Notes 2019; 12:199. [PMID: 30940215 PMCID: PMC6446403 DOI: 10.1186/s13104-019-4237-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 03/28/2019] [Indexed: 11/25/2022] Open
Abstract
Objective To evaluates the effect of food intake on 92 oncological biomarkers to evaluate whether the timing of blood sampling could be relevant. Twenty-two healthy subjects were investigated. A total of 92 biomarkers were measured before a standardised meal as well as 30 and 120 min afterwards with the Proseek Multiplex Oncology II kit. Results The levels of 6 biomarkers decreased significantly (P < 0.001) 30 min after food intake, and 4 biomarkers remained decreased (P < 0.001) 120 min after food intake. One biomarker was significantly increased (P < 0.001) at both 30 and 120 min after food intake. Some changes were less than 10%. Those biomarkers that showed a difference of more than 10% include: Granzyme H (13%), Methionine aminopeptidase 2 (14%), Secretory carrier-associated membrane protein 3 (39%), FAS-associated death domain protein (41%), and Pancreatic prohormone (79%). This study shows that food intake has a very modest effect on 92 different oncological biomarkers. Trial registration National Library of Medicine trial registration number NCT01027507 (retrospectively registered on December 8, 2009)
Collapse
Affiliation(s)
- Magnus Dencker
- Department of Medical Imaging and Physiology, Skåne University Hospital, Lund University, 205 02, Malmö, Sweden.
| | - Ola Björgell
- Department of Medical Imaging and Physiology, Skåne University Hospital, Lund University, 205 02, Malmö, Sweden
| | - Joanna Hlebowicz
- Department of Clinical Sciences, Division of Medicine, Skåne University Hospital, Lund University, Malmö, Sweden
| |
Collapse
|
7
|
De Smit E, Lukowski SW, Anderson L, Senabouth A, Dauyey K, Song S, Wyse B, Wheeler L, Chen CY, Cao K, Wong Ten Yuen A, Shuey N, Clarke L, Lopez Sanchez I, Hung SSC, Pébay A, Mackey DA, Brown MA, Hewitt AW, Powell JE. Longitudinal expression profiling of CD4+ and CD8+ cells in patients with active to quiescent giant cell arteritis. BMC Med Genomics 2018; 11:61. [PMID: 30037347 PMCID: PMC6057030 DOI: 10.1186/s12920-018-0376-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 06/26/2018] [Indexed: 12/15/2022] Open
Abstract
Background Giant cell arteritis (GCA) is the most common form of vasculitis affecting elderly people. It is one of the few true ophthalmic emergencies but symptoms and signs are variable thereby making it a challenging disease to diagnose. A temporal artery biopsy is the gold standard to confirm GCA, but there are currently no specific biochemical markers to aid diagnosis. We aimed to identify a less invasive method to confirm the diagnosis of GCA, as well as to ascertain clinically relevant predictive biomarkers by studying the transcriptome of purified peripheral CD4+ and CD8+ T lymphocytes in patients with GCA. Methods We recruited 16 patients with histological evidence of GCA at the Royal Victorian Eye and Ear Hospital, Melbourne, Australia, and aimed to collect blood samples at six time points: acute phase, 2–3 weeks, 6–8 weeks, 3 months, 6 months and 12 months after clinical diagnosis. CD4+ and CD8+ T-cells were positively selected at each time point through magnetic-assisted cell sorting. RNA was extracted from all 195 collected samples for subsequent RNA sequencing. The expression profiles of patients were compared to those of 16 age-matched controls. Results Over the 12-month study period, polynomial modelling analyses identified 179 and 4 statistically significant transcripts with altered expression profiles (FDR < 0.05) between cases and controls in CD4+ and CD8+ populations, respectively. In CD8+ cells, two transcripts remained differentially expressed after 12 months; SGTB, associated with neuronal apoptosis, and FCGR3A, associatied with Takayasu arteritis. We detected genes that correlate with both symptoms and biochemical markers used for predicting long-term prognosis. 15 genes were shared across 3 phenotypes in CD4 and 16 across CD8 cells. In CD8, IL32 was common to 5 phenotypes including Polymyalgia Rheumatica, bilateral blindness and death within 12 months. Conclusions This is the first longitudinal gene expression study undertaken to identify robust transcriptomic biomarkers of GCA. Our results show cell type-specific transcript expression profiles, novel gene-phenotype associations, and uncover important biological pathways for this disease. In the acute phase, the gene-phenotype relationships we have identified could provide insight to potential disease severity and as such guide in initiating appropriate patient management. Electronic supplementary material The online version of this article (10.1186/s12920-018-0376-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Elisabeth De Smit
- Centre for Eye Research Australia, The University of Melbourne, Royal Victorian Eye & Ear Hospital, 32 Gisborne Street, East Melbourne, 3002, Australia.
| | - Samuel W Lukowski
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, 4072, Queensland, Australia
| | - Lisa Anderson
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Brisbane, 4102, Queensland, Australia
| | - Anne Senabouth
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, 4072, Queensland, Australia
| | - Kaisar Dauyey
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, 4072, Queensland, Australia
| | - Sharon Song
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Brisbane, 4102, Queensland, Australia
| | - Bruce Wyse
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Brisbane, 4102, Queensland, Australia
| | - Lawrie Wheeler
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Brisbane, 4102, Queensland, Australia
| | - Christine Y Chen
- Ophthalmology Department at Monash Health, Department of Surgery, School of Clinical Sciences at Monash Health, Melbourne, 3168, Victoria, Australia
| | - Khoa Cao
- Ophthalmology Department at Monash Health, Department of Surgery, School of Clinical Sciences at Monash Health, Melbourne, 3168, Victoria, Australia
| | - Amy Wong Ten Yuen
- Centre for Eye Research Australia, The University of Melbourne, Royal Victorian Eye & Ear Hospital, 32 Gisborne Street, East Melbourne, 3002, Australia
| | - Neil Shuey
- Department of Neuro-Ophthalmology, Royal Victorian Eye and Ear Hospital, Melbourne, 3002, Victoria, Australia
| | - Linda Clarke
- Centre for Eye Research Australia, The University of Melbourne, Royal Victorian Eye & Ear Hospital, 32 Gisborne Street, East Melbourne, 3002, Australia
| | - Isabel Lopez Sanchez
- Centre for Eye Research Australia, The University of Melbourne, Royal Victorian Eye & Ear Hospital, 32 Gisborne Street, East Melbourne, 3002, Australia
| | - Sandy S C Hung
- Centre for Eye Research Australia, The University of Melbourne, Royal Victorian Eye & Ear Hospital, 32 Gisborne Street, East Melbourne, 3002, Australia
| | - Alice Pébay
- Centre for Eye Research Australia, The University of Melbourne, Royal Victorian Eye & Ear Hospital, 32 Gisborne Street, East Melbourne, 3002, Australia
| | - David A Mackey
- Centre for Ophthalmology and Visual Science, The University of Western Australia, Lions Eye Institute, Perth, 6009, Western Australia, Australia
| | - Matthew A Brown
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Brisbane, 4102, Queensland, Australia
| | - Alex W Hewitt
- Centre for Eye Research Australia, The University of Melbourne, Royal Victorian Eye & Ear Hospital, 32 Gisborne Street, East Melbourne, 3002, Australia.,School of Medicine, Menzies Research Institute Tasmania, University of Tasmania, Hobart, 7000, Tasmania, Australia
| | - Joseph E Powell
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, 4072, Queensland, Australia
| |
Collapse
|
8
|
Jaime-Sánchez P, Catalán E, Uranga-Murillo I, Aguiló N, Santiago L, M Lanuza P, de Miguel D, A Arias M, Pardo J. Antigen-specific primed cytotoxic T cells eliminate tumour cells in vivo and prevent tumour development, regardless of the presence of anti-apoptotic mutations conferring drug resistance. Cell Death Differ 2018; 25:1536-1548. [PMID: 29743559 DOI: 10.1038/s41418-018-0112-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 03/20/2018] [Accepted: 03/22/2018] [Indexed: 02/06/2023] Open
Abstract
Cytotoxic CD8+ T (Tc) cells are the main executors of transformed and cancer cells during cancer immunotherapy. The latest clinical results evidence a high efficacy of novel immunotherapy agents that modulate Tc cell activity against bad prognosis cancers. However, it has not been determined yet whether the efficacy of these treatments can be affected by selection of tumoural cells with mutations in the cell death machinery, known to promote drug resistance and cancer recurrence. Here, using a model of prophylactic tumour vaccination based on the LCMV-gp33 antigen and the mouse EL4 T lymphoma, we analysed the molecular mechanism employed by Tc cells to eliminate cancer cells in vivo and the impact of mutations in the apoptotic machinery on tumour development. First of all, we found that Tc cells, and perf and gzmB are required to efficiently eliminate EL4.gp33 cells after LCMV immunisation during short-term assays (1-4 h), and to prevent tumour development in the long term. Furthermore, we show that antigen-pulsed chemoresistant EL4 cells overexpressing Bcl-XL or a dominant negative form of caspase-3 are specifically eliminated from the peritoneum of infected animals, as fast as parental EL4 cells. Notably, antigen-specific Tc cells control the tumour growth of the mutated cells, as efficiently as in the case of parental cells. Altogether, expression of the anti-apoptotic mutations does not confer any advantage for tumour cells neither in the short-term survival nor in long-term tumour formation. Although the mechanism involved in the elimination of the apoptosis-resistant tumour cells is not completely elucidated, neither necroptosis nor pyroptosis seem to be involved. Our results provide the first experimental proof that chemoresistant cancer cells with mutations in the main cell death pathways are efficiently eliminated by Ag-specific Tc cells in vivo during immunotherapy and, thus, provide the molecular basis to treat chemoresistant cancer cells with CD8 Tc-based immunotherapy.
Collapse
Affiliation(s)
- Paula Jaime-Sánchez
- Biomedical Research Centre of Aragon (CIBA), IIS Aragon/University of Zaragoza, Zaragoza, Spain
| | - Elena Catalán
- Department of Biochemistry and Molecular and Cell Biology, University of Zaragoza, Zaragoza, Spain
| | - Iratxe Uranga-Murillo
- Biomedical Research Centre of Aragon (CIBA), IIS Aragon/University of Zaragoza, Zaragoza, Spain
| | - Nacho Aguiló
- Dept. Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain.,CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
| | - Llipsy Santiago
- Biomedical Research Centre of Aragon (CIBA), IIS Aragon/University of Zaragoza, Zaragoza, Spain
| | - Pilar M Lanuza
- Biomedical Research Centre of Aragon (CIBA), IIS Aragon/University of Zaragoza, Zaragoza, Spain
| | - Diego de Miguel
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London, 72 Huntley Street, London, WC1E 6DD, UK
| | - Maykel A Arias
- Biomedical Research Centre of Aragon (CIBA), IIS Aragon/University of Zaragoza, Zaragoza, Spain.
| | - Julián Pardo
- Biomedical Research Centre of Aragon (CIBA), IIS Aragon/University of Zaragoza, Zaragoza, Spain. .,Dept. Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain. .,Nanoscience Institute of Aragon (INA), University of Zaragoza, Zaragoza, Spain. .,Aragon I+D Foundation, Zaragoza, Spain.
| |
Collapse
|
9
|
Granzyme K‐deficient mice show no evidence of impaired antiviral immunity. Immunol Cell Biol 2017; 95:676-683. [DOI: 10.1038/icb.2017.35] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Revised: 04/13/2017] [Accepted: 04/13/2017] [Indexed: 01/16/2023]
|
10
|
|
11
|
|